Arno Furquim d’Almeida

Mr. Arno Furquim d’Almeida

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2024 in Journal of Hepatology
Verified
Journal Article
Open access
EDEdo J. Dongelmans
Edo J. Dongelmans
GHGrishma Hirode
Grishma Hirode
BHBettina E. Hansen
Bettina E. Hansen
CCChien-Hung Chen
Chien-Hung Chen
TSTung-Hung Su
Tung-Hung Su
HJHarry L.A. Janssen
Harry L.A. Janssen
Flares after nucleos(t)ide analogue (NA) cessation are common and potentially harmful. Predictors of flares are required for risk stratification and to guide off-treatment follow-up. This multicenter cohort study included virally suppressed patients with chronic hepatitis B (CHB) who were hepatitis B e antigen negative at NA cessation. Hepatic flares were defined based on ALT levels of ≥5x, 10x or 20x the upper limit of normal (ULN). Multivariable Cox regression analyses were performed with censoring at retreatment, HBsAg loss or loss to follow-up. A sub-analysis was performed including HBV DNA levels within the first 12 weeks as a time-dependent covariate. Of the 1,552 included patients, 350 developed a flare (ALT ≥5x ULN), of whom 70.6% did within the first year. One-year cumulative incidences for ALT flares ≥5x, ≥10x, ≥20x ULN were 18.6%, 10.2% and 3.4%, respectively. Severity of flares decreased over time, but severe flares still occurred after 1 year. Thirteen patients decompensated after a flare, of whom three died. Flares did not seem to be associated with increased rates of HBsAg loss (adjusted hazard ratio [aHR] 1.42, p = 0.28). Multivariable analyses showed that older age (aHR 1.02, p = 0.001), male sex (aHR 1.57, p = 0.003), HBsAg levels at NA withdrawal (100-1,000 IU/ml; aHR 1.99, p 1,000 IU/ml; aHR 2.65, p <0.001) and tenofovir disoproxil fumarate vs. entecavir therapy (aHR 2.99, p 5log10 IU/ml were associated with the highest risk of flares (aHR 2.36, p <0.001). Flares are common after NA withdrawal, especially within the first year and can result in hepatic decompensation and death. Older age, male sex, higher HBsAg levels at end of treatment and tenofovir therapy were associated with a higher risk of flares. Close monitoring and retreatment should be considered if HBV DNA levels exceed 5log10 IU/ml within the first 12 weeks. This is the first large global multi-centered cohort study which provides detailed data about flares after nucleos(t)ide analogue cessation in patients with chronic hepatitis B. Older age, male sex, higher HBsAg levels at end of treatment and tenofovir therapy were associated with a higher risk of flares. These results could guide follow-up after withdrawal, helping clinicians identify high-risk patients and decide when to restart anti-viral therapy, which we recommend if HBV DNA levels exceed 5log10 IU/ml within the first 12 weeks. not applicable.

14 May 2024 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
GHGrishma Hirode
Grishma Hirode
BHBettina E. Hansen
Bettina E. Hansen
CCChien-Hung Chen
Chien-Hung Chen
TSTung-Hung Su
Tung-Hung Su
GWGrace Lai-Hung Wong
Grace Lai-Hung Wong
OGon behalf of the RETRACT-B study group
on behalf of the RETRACT-B study group
INTRODUCTION: Complete viral suppression with nucleos(t)ide analogs (NAs) has led to a profound reduction in hepatocellular carcinoma and mortality among patients with chronic hepatitis B. Finite therapy yields higher rates of functional cure; however, initial hepatitis B virus (HBV) DNA and alanine aminotransferase (ALT) elevations are almost certain after treatment interruption. We aimed to analyze off-treatment outcomes beyond 12 months after NA cessation. METHODS: Patients with well-suppressed chronic hepatitis B who were hepatitis B e antigen-negative at NA cessation and remained off treatment without hepatitis B surface antigen (HBsAg) loss at 12 months were included (n = 945). HBV DNA and ALT fluctuations were allowed within the first 12 months. We used Kaplan-Meier methods to analyze outcomes beyond 12 months. Sustained remission was defined as HBV DNA <2,000 IU/mL and ALT <2× upper limit of normal (ULN) and an ALT flare as ALT ≥5× ULN. RESULTS: Cumulative probability of sustained remission was 29.7%, virological relapse was 65.2% with a mean peak HBV DNA of 5.0 ± 1.5 log10 IU/mL, an ALT flare was 15.6% with a median peak ALT × ULN of 8.3 (5.7–11.3), HBsAg loss was 9.9% and retreatment was 34.9% at 48 months after NA cessation. A single occurrence of virological relapse or an ALT flare within the first 12 months off-treatment were associated with significantly lower rates of sustained remission beyond 12 months. DISCUSSION: Despite allowing for HBV DNA and ALT fluctuations within the first 12 months off-treatment, most patients without HBsAg loss did not maintain a sustained response thereafter. The best candidates for NA withdrawal are patients with low HBsAg levels at NA cessation, and those without profound or recurrent virological and biochemical relapses in the first off-treatment year.

30 November 2021 in United European Gastroenterology Journal
Verified
Journal Article
Open access
PDF file
ADArno Furquim d’Almeida
Arno Furquim d’Almeida
EHErwin Ho
Erwin Ho
SHStijn Van Hees
Stijn Van Hees
TVThomas Vanwolleghem
Thomas Vanwolleghem
Worldwide, over 250 million people are chronically infected with the hepatitis B virus (HBV). Infected patients have an up to 100‐fold increased risk for liver‐related complications, including cirrhosis, hepatic decompensation and hepatocellular carcinoma. Nonetheless, the majority of the infections remains asymptomatic, stressing the importance of HBV screening and linkage to care. Excellent clinical outcomes are seen during nucleos(t)ide analogue (NA) therapy, which often is continued indefinitively due to a lack of functional cure. Increasing evidence suggests that NA discontinuation following long‐term treatment induced viral suppression in patients without a functional cure may be a favourable option. Reliable biomarkers are, however, urgently needed to select the patients that would benefit from NA withdrawal. In addition, renewed and novel approaches to improve screening and linkage to care are other fundamental factors in the optimisation of the clinical management of chronic hepatitis B.

23 January 2025 in Journal of Viral Hepatitis
Verified
Journal Article
Open access
ADArno Furquim d’Almeida
Arno Furquim d’Almeida
EHErwin Ho
Erwin Ho
LGLiesbeth Govaerts
Liesbeth Govaerts
PMPeter Michielsen
Peter Michielsen
TSThomas Sersté
Thomas Sersté
TVThomas Vanwolleghem
Thomas Vanwolleghem
Hepatitis B virus (HBV)–hepatitis delta virus (HDV) coinfection is the most severe form of chronic viral hepatitis, but the factors that determine disease progression and severity are incompletely characterised. This long‐term follow‐up study aims to identify risk factors for severe liver‐related outcomes. In this multicentre national cohort study, data from admission until the last visit between 2001 and 2023 was retrospectively collected from 162 HBV‐HDV coinfected patients. The inclusion criteria were HBsAg or HBV DNA positivity, anti‐HDV or HDV RNA positivity, and at least one follow‐up visit. The median follow‐up was 6.2 years (IQR 3.3–10.2). At baseline, 68/152 (44.7%) patients were diagnosed with advanced liver fibrosis. Forty patients (24.7%) had at least one severe liver‐related outcome during follow‐up. HDV viremia was detectable in 92 patients (64.3%) at last evaluation and was more frequently detectable in patients of European origin (p < 0.001). HDV RNA‐positive patients had a 4.7‐fold higher risk for severe liver‐related outcomes (p < 0.001) and were more frequently diagnosed with advanced fibrosis at baseline (p = 0.007) compared to HDV RNA‐negative patients. Multivariate analyses identified HDV RNA positivity, as well as several markers for liver disease severity, such as INR, platelet count, and advanced fibrosis at baseline, and age at admission as independent risk factors for severe liver‐related outcomes. In conclusion, almost one in four HBV‐HDV coinfected patients developed a severe liver‐related outcome during follow‐up. Several markers for liver disease severity and HDV RNA positivity were the strongest predictors for outcomes.

19 November 2025 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
ADArno Furquim d’Almeida
Arno Furquim d’Almeida
AVAxelle Vanderlinden
Axelle Vanderlinden
SBStefan Bourgeois
Stefan Bourgeois
JMJean‐Pierre Mulkay
Jean‐Pierre Mulkay
TSThomas Sersté
Thomas Sersté
TVThomas Vanwolleghem
Thomas Vanwolleghem

19 May 2026 in JHEP Reports
Verified
Journal Article
Open access
SLSabela Lens
Sabela Lens
HKHabiba Kamal
Habiba Kamal
ADArno Furquim d’Almeida
Arno Furquim d’Almeida
SBSara Battistella
Sara Battistella
SBSegolene Brichler
Segolene Brichler
JCJose Luis Calleja
Jose Luis Calleja
Hepatitis delta virus (HDV) is the most aggressive form of chronic viral hepatitis. As new therapies emerge, a clearer understanding of its natural history - particularly in early disease stages - is needed. We assessed real-world outcomes of HDV-infected patients with mild-to-moderate fibrosis and identified predictors of progression to cirrhosis. We performed a multicenter, international, retrospective study including adult patients with active HDV infection (HDV-RNA positive) and no advanced fibrosis at baseline, confirmed by histology or liver stiffness measurement (TE-LSM) within the first year of diagnosis. Demographic, clinical, biochemical, and virological variables were collected at baseline and annually thereafter. The primary outcome was development of cirrhosis; secondary outcomes included liver-related events and longitudinal changes in fibrosis markers. The cohort included 168 patients (median age 37.5 [31-45] years; 53% male; 56% Caucasian). Fewer than 15% had HIV/HCV coinfection or metabolic/alcohol-related risk factors. At baseline, 36% had ALT ≥2 × the upper limit of normal and median TE-LSM was 7.6 (6-9) kPa. Over a median follow-up of 62 (40-94) months, 37 patients (22%) developed cirrhosis. Two developed ascites (one required liver transplantation), and one developed hepatocellular carcinoma and died. HDV clearance occurred in 32 patients (19%), either spontaneously (n = 14) or after antiviral therapy (n = 18). In the multivariate analysis, only TE-LSM ≥7 kPa independently predicted progression (HR 6.02 [1.76-20.6]; p = 0.004). FIB-4 ≥1.45 also identified higher-risk patients when TE-LSM was unavailable (HR 3.51 [1.68-7.34]; p <0.01). Neither antiviral therapy nor changes on HDV RNA or ALT overtime remained as independent predictors. Despite mild-to-moderate baseline fibrosis, over 20% of patients progressed to cirrhosis within 5 years. Baseline non-invasive markers effectively stratify risk and may inform prioritization of emerging HDV therapies. Patients with HDV and mild-to-moderate fibrosis remain at substantial risk of progression, with more than 20% developing cirrhosis during a median follow-up of 5 years. Liver stiffness measured by transient elastography (TE-LSM) was the strongest predictor of progression. FIB-4 may have a prognostic value when TE-LSM is not available, whereas ALT levels and HDV-RNA, both at baseline and during follow-up, did not influence fibrosis outcomes. These findings support improved early risk stratification and may help clinicians identify which patients with apparently early-stage disease warrant closer monitoring or timely treatment intervention.